stock analysing on white printed paper yellow pencil and black calculator

Puma Biotechnology, Inc. [PBYI] took an upward turn with a change of 7.11%, trading at the price of $10.16 during the trading session on . The price movement in correlation with percentage of the mentioned increase can allow a valuable insight to investors. During the last trading session 1.83 million shares changed hands being bought and sold, while Puma Biotechnology, Inc. shares have an average trading volume of 1.59M shares for that time period. PBYI monthly volatility recorded 8.35%, in the meanwhile having share price volatility for the week set at 5.90%. PS value for PBYI stocks is 1.28 with PB recorded at 21.57.

Puma Biotechnology, Inc. [NASDAQ:PBYI]: Analyst Rating and Earnings

Its stock price has been found in the range of 6.26 to 43.90. This is compared to its latest closing price of $9.49.

Keep on the lookout for this organization’s next scheduled financial results, which are expected to be made public on Thu 27 Feb (In 87 Days).

Fundamental Analysis of Puma Biotechnology, Inc. [PBYI]

Now let’s turn to look at profitability: with a current Operating Margin for Puma Biotechnology, Inc. [PBYI] sitting at -37.72 and its Gross Margin at +86.21, this company’s Net Margin is now -33.90%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.

This company’s Return on Total Capital is -65.75, and its Return on Invested Capital has reached -55.70%. Its Return on Equity is -259.28, and its Return on Assets is -53.49. These metrics suggest that this Puma Biotechnology, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organization’s capital structure, Puma Biotechnology, Inc. [PBYI] has generated a Total Debt to Total Equity ratio of 442.74. Similarly, its Total Debt to

Total Capital is 81.57, while its Total Debt to Total Assets stands at 58.62. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is -8.62, and its Long-Term Debt to Total Capital is 442.74.

What about valuation? This company’s Enterprise Value to EBITDA is -4.08. The Enterprise Value to Sales for this firm is now 1.27, and its Total Debt to Enterprise Value stands at 0.20. Puma Biotechnology, Inc. [PBYI] has a Price to Book Ratio of 22.73.

Shifting the focus to workforce efficiency, Puma Biotechnology, Inc. [PBYI] earns $922,761 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 15.88 and its Total Asset Turnover is 1.18. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 2.99 and its Current Ratio is 3.02. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Puma Biotechnology, Inc. [PBYI] has 37.69M shares outstanding, amounting to a total market cap of $357.68M. Its stock price has been found in the range of 6.26 to 43.90. At its current price, it has moved down by -76.85% from its 52-week high, and it has moved up 62.38% from its 52-week low.

This stock’s Beta value is currently 1.67, which indicates that it is 5.90% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 65.10. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is Puma Biotechnology, Inc. [PBYI] a Reliable Buy?

Shares of Puma Biotechnology, Inc. [PBYI], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.